Medical comms - Articles
With bacteriological diseases such as SARS and MRSA on the increase and with concern about these diseases at an all time high, the medical community is under tremendous pressure to implement measures in order to minimise the risk of potential outbreaks.
With bacteriological diseases such as SARS and MRSA on the increase and with concern about these diseases at an all time high, the medical community is under tremendous pressure to implement measures in order to minimise the risk of potential outbreaks. Recent official reports suggest that MRSA can be found in 40 per cent of UK hospitals . Transmission occurs through coming into contact with an object carrying the bacteria or via direct skin-to-skin exposure. Hospitals therefore have an up-hill struggle to eradicate superbugs. …
With bacteriological diseases such as SARS and MRSA on the increase and with concern about these diseases at an all time high, the medical community is under tremendous pressure to implement measures in order to minimise the risk of potential outbreaks. Recent official reports suggest that MRSA can be found in 40 per cent of UK hospitals . Transmission occurs through coming into contact with an object carrying the bacteria or via direct skin-to-skin exposure. Hospitals therefore have an up-hill struggle to eradicate superbugs. …
27-Aug-2010
The symptoms of Alzheimer’s disease can be treated by a class of drugs known as cholinesterase inhibitors (ChEI’s), which increase the availability of acetylcholine in the brain by inhibiting the enzyme acetylcholinesterase (AChE).
Dementia is a neurodegenerative and devastating disease Dementia is a degenerative disease of the brain that progressively destroys the neurons controlling memory, language and reasoning. It progresses at different rates in different people. It is estimated that dementia currently affects nearly 18 million people worldwide (1). As the mean age of the population increases, these numbers are steadily increasing. Forms of dementia and their estimated prevalence: 1 Alzheimer's disease (AD) 55% Vascular dementia (VaD)20% Dementia with Lewy bodies (DLB) and dementia…
Dementia is a neurodegenerative and devastating disease Dementia is a degenerative disease of the brain that progressively destroys the neurons controlling memory, language and reasoning. It progresses at different rates in different people. It is estimated that dementia currently affects nearly 18 million people worldwide (1). As the mean age of the population increases, these numbers are steadily increasing. Forms of dementia and their estimated prevalence: 1 Alzheimer's disease (AD) 55% Vascular dementia (VaD)20% Dementia with Lewy bodies (DLB) and dementia…
27-Aug-2010
The size of the cytotoxic market in the seven major pharmaceutical markets is estimated to be approximately $9.6 billion. Datamonitor expects it to reach a peak of $12.8 billion by 2009. However, mainly due to major patent expiries, it is expected to drop to $11.3 billion by 2014. Topoisomerase inhibitors represent a subgroup of the plant alkaloid class of cytotoxics. DNA topoisomerase II inhibitors are among the most efficacious drugs for the treatment of cancer although they are associated wi
DailyUpdates 3rd February, 2006: The size of the cytotoxic market in the seven major pharmaceutical markets is estimated to be approximately $9.6 billion. Datamonitor expects it to reach a peak of $12.8 billion by 2009. However, mainly due to major patent expiries, it is expected to drop to $11.3 bi…
DailyUpdates 3rd February, 2006: The size of the cytotoxic market in the seven major pharmaceutical markets is estimated to be approximately $9.6 billion. Datamonitor expects it to reach a peak of $12.8 billion by 2009. However, mainly due to major patent expiries, it is expected to drop to $11.3 bi…
The market for antibacterials, valued at $24 billion in the seven major markets, faces significant revenue loss in the period 2005-2007 due to major patent expiries. In exception, considerable success has been met by those targeting drug resistant infections. This is highlighted by the rapid uptake of products focused on drug-resistant infections, such as Pfizer's Zyvox (linezolid). Here we highlight a promising early stage candidate being developed by Replidyne, REP8839
The market for antibacterials, valued at $24 billion in the seven major markets, faces significant revenue loss in the period 2005-2007 due to major patent expiries (see Commercial Insight: Antibacterials). Despite the problems faced by companies involved in antibacterials considerable success has been met by th…
The market for antibacterials, valued at $24 billion in the seven major markets, faces significant revenue loss in the period 2005-2007 due to major patent expiries (see Commercial Insight: Antibacterials). Despite the problems faced by companies involved in antibacterials considerable success has been met by th…
OX40 (CD134) is one of the newer tumor necrosis factor receptor (TNFR) family members. Expressed on CD4+ T-cells, its activation by OX40L, a type II membrane protein expressed on activated B-cells, dendritic cells and macrophages, plays an important T-cell co-stimulatory role. Today we highlight additional involvement in heart disease
DailyUpdates Jan 31st: OX40:OX40L interaction – evolving from a key component of autoimmunity to a possible target for cardiovascular disease OX40 (CD134) is one of the newer tumor necrosis factor receptor (TNFR) family members. Expressed on CD4+ T-cells, its activation by OX40L, a type II membrane protein expressed on activated B-cells, dendritic cells and macrophages, plays an important T-cell co-stimulatory role. In our recent feature on Autoimmun…
DailyUpdates Jan 31st: OX40:OX40L interaction – evolving from a key component of autoimmunity to a possible target for cardiovascular disease OX40 (CD134) is one of the newer tumor necrosis factor receptor (TNFR) family members. Expressed on CD4+ T-cells, its activation by OX40L, a type II membrane protein expressed on activated B-cells, dendritic cells and macrophages, plays an important T-cell co-stimulatory role. In our recent feature on Autoimmun…
Genomics and proteomics comprise a fundamental area of bioinformatics however exploiting the wealth of information gained using such disciplines remains a rate limiting step in the drug discovery process. Today’s edition of DailyUpdates (Jan 25th 2005) describes ground breaking work that has allowed researchers to identify candidate therapeutics for the treatment of SARs virus infection in under a month using the virus genome as a starting point
Source DailyUpdates Jan 25th: As information technology becomes increasingly important in drug R&D, the application of bioinformatics/informatics applications has the potential to drive growth in the worldwide pharmaceuticals drug market from the $240 billion today to $3 trillion by 2020.The role of bioinformatics/informatics in the drug d…
Source DailyUpdates Jan 25th: As information technology becomes increasingly important in drug R&D, the application of bioinformatics/informatics applications has the potential to drive growth in the worldwide pharmaceuticals drug market from the $240 billion today to $3 trillion by 2020.The role of bioinformatics/informatics in the drug d…
In 1999 Human Genome Sciences researchers published a study in the journal Science describing a new member of the TNF super-family which they named BLyS. Since that time our understanding of this protein, also known as BAFF, and its homologue APRIL has progressed rapidly. The BAFF sub-family has emerged as a candidate target for therapies of various autoimmune diseases and hematological cancers with breathtaking speed.
In 1999 Human Genome Sciences researchers published a study in the journal Science describing a new member of the TNF super-family which they named BLyS. Since that time our understanding of this protein, also known as BAFF, and its homologue APRIL has progressed rapidly. The BAFF sub-family has emerged as a candidate target for therapies of various autoimmune diseases…
In 1999 Human Genome Sciences researchers published a study in the journal Science describing a new member of the TNF super-family which they named BLyS. Since that time our understanding of this protein, also known as BAFF, and its homologue APRIL has progressed rapidly. The BAFF sub-family has emerged as a candidate target for therapies of various autoimmune diseases…
A new study shows the oral iron-chelator Ferriprox (deferiprone) prevents patients with thalassaemia experiencing heart complications and dying of heart failure. Patients with the condition require frequent blood transfusions with the unwanted effect of excess iron that can build up in organs and endocrine glands. Iron overload in the heart can produce fatal complications so effective treatment with iron chelation therapy to remove iron is vital. The finding that an oral treatment achieves bett
A new study shows the oral iron-chelator Ferriprox (deferiprone) prevents patients with thalassaemia experiencing heart complications and dying of heart failure. Patients with the condition require frequent blood transfusions with the unwanted effect of excess iron that can build up in organs…
A new study shows the oral iron-chelator Ferriprox (deferiprone) prevents patients with thalassaemia experiencing heart complications and dying of heart failure. Patients with the condition require frequent blood transfusions with the unwanted effect of excess iron that can build up in organs…
There is little mystery about what the next few years hold for the clinical research industry –it comes down to one word: speed. It is all about speed. The gauntlet has been thrown down and the companies that are able to demonstrate an effective and consistent approach to truncating the timeline of clinical trials will be very successful.
By: Brian S. Robinson i3, Vice-President, Global Marketing www.i3global.com There is little mystery about what the next few years hold for the clinical research industry –it comes down to one word: speed. It is all about speed. The gauntlet has been thrown down and the companies that are able to demonstrate an effective and consistent approach to truncating the timeline of clinical trials will be very successful. Speed is not a capabili…
By: Brian S. Robinson i3, Vice-President, Global Marketing www.i3global.com There is little mystery about what the next few years hold for the clinical research industry –it comes down to one word: speed. It is all about speed. The gauntlet has been thrown down and the companies that are able to demonstrate an effective and consistent approach to truncating the timeline of clinical trials will be very successful. Speed is not a capabili…
27-Aug-2010
Electronic Data Capture (EDC), three little words that can divide the clinical research community like few others. To some, EDC is a panacea for all the troubles and rising costs of the clinical development process, whilst to others it spells broken promises, and forms the butt of many less than flattering anecdotes.
Electronic Data Capture (EDC), three little words that can divide the clinical research community like few others. To some, EDC is a panacea for all the troubles and rising costs of the clinical development process, whilst to others it spells broken promises, and forms the butt of many less than flattering anecdotes. But what is the reality, and where is the border between the promise of providers and the expectation of end users? This article is not designed to provide d…
Electronic Data Capture (EDC), three little words that can divide the clinical research community like few others. To some, EDC is a panacea for all the troubles and rising costs of the clinical development process, whilst to others it spells broken promises, and forms the butt of many less than flattering anecdotes. But what is the reality, and where is the border between the promise of providers and the expectation of end users? This article is not designed to provide d…
27-Aug-2010
Free Job Postings for UK Charity Organisations in the Healthcare Sector.
If you are a UK registered charity in the healthcare sector, we can offer you FREE job postings. So, you can access 160,000 visitors per month for nothing! If you want to know more contact Mike Wood
If you are a UK registered charity in the healthcare sector, we can offer you FREE job postings. So, you can access 160,000 visitors per month for nothing! If you want to know more contact Mike Wood
27-Aug-2010
New Blog for Jobs
As part of our continuing development and improvement, we have added created a Blog of our Top Jobs. This will be updated weekly and will also include any other news or information we think is relevant relevant to Pharmaceutical job searching. Check it out here: http://pharmaceuticaljobs.blogspot.com/
As part of our continuing development and improvement, we have added created a Blog of our Top Jobs. This will be updated weekly and will also include any other news or information we think is relevant relevant to Pharmaceutical job searching. Check it out here: http://pharmaceuticaljobs.blogspot.com/
27-Aug-2010
Dr Adam Meijer of the Netherlands-based European Influenza Surveillance Scheme (EISS)§ has highlighted the vital role rapid testing must play in combating the global threat of bird flu. Dr Meijer makes his observations in the January issue of Expert Review of Molecular Diagnostics.
Dr Adam Meijer of the Netherlands-based European Influenza Surveillance Scheme (EISS)§ has highlighted the vital role rapid testing must play in combating the global threat of bird flu. Dr Meijer makes his observations in the January issue of Expert Review of Molecular Diagnostics. Until now, the last requirement for avian influenza viruses to cause a pandemic – efficient transmission between humans – has fortunately not been met. However, the devastating effect of the A(H5N1) bird flu on poultry holdings, and he…
Dr Adam Meijer of the Netherlands-based European Influenza Surveillance Scheme (EISS)§ has highlighted the vital role rapid testing must play in combating the global threat of bird flu. Dr Meijer makes his observations in the January issue of Expert Review of Molecular Diagnostics. Until now, the last requirement for avian influenza viruses to cause a pandemic – efficient transmission between humans – has fortunately not been met. However, the devastating effect of the A(H5N1) bird flu on poultry holdings, and he…
New data presented at the American Society of Hematology meeting in Atlanta this month suggest the problems associated with iron overload in frequently-transfused patients can now be managed simply with an oral treatment rather than continuous infusions of several hours duration.
New data presented at the American Society of Hematology meeting in Atlanta this month suggest the problems associated with iron overload in frequently-transfused patients can now be managed simply with an oral treatment rather than continuous infusions of several hours duration. Iron was removed from the blood and tissues of patients just as safely and effectively with the novel once-daily oral chelator treatment deferasirox (Exjade) as with the standard older injectable iron chelator deferoxamine. Th…
New data presented at the American Society of Hematology meeting in Atlanta this month suggest the problems associated with iron overload in frequently-transfused patients can now be managed simply with an oral treatment rather than continuous infusions of several hours duration. Iron was removed from the blood and tissues of patients just as safely and effectively with the novel once-daily oral chelator treatment deferasirox (Exjade) as with the standard older injectable iron chelator deferoxamine. Th…
Most patients who develop chronic myeloid leukaemia (CML) can now expect to live more than 20 years from diagnosis if they are treated with the tyrosine kinase inhibitor (TKI) Glivec (imatinib) according to haematologists involved in the IRIS (International Randomized Interferon versus STI571) study. Before availability of current treatments, median survival from diagnosis was 3.5 years.
Most patients who develop chronic myeloid leukaemia (CML) can now expect to live more than 20 years from diagnosis if they are treated with the tyrosine kinase inhibitor (TKI) Glivec (imatinib) according to haematologists involved in the IRIS (International Randomized Interferon versus STI571) study. Before availability of current treatments, median survival from diagnosis was 3.5 years. Around 95 pe…
Most patients who develop chronic myeloid leukaemia (CML) can now expect to live more than 20 years from diagnosis if they are treated with the tyrosine kinase inhibitor (TKI) Glivec (imatinib) according to haematologists involved in the IRIS (International Randomized Interferon versus STI571) study. Before availability of current treatments, median survival from diagnosis was 3.5 years. Around 95 pe…
27-Aug-2010
Together, the four major cancer markets, which include colorectal, prostate, lung and breast cancer, were valued at well over $16 billion in 2005, which was an increase of 14 percent in value since 2004. Driving this growth are innovative new products, line extensions for existing products, and the coming of age of the biotech industry.
New Biologics revolutionizing treatment of colorectal cancer The market for colorectal cancer therapies has increased by over seven-fold since 2000. The increase in the value of this market can be explained by new and improved chemotherapeutic agents now on the market, the introduction of key biologic therapies, and improved chemotherapeutic regimens which take into account various new options. The late-stage pipeline for colorectal cancer therapies is curr…
New Biologics revolutionizing treatment of colorectal cancer The market for colorectal cancer therapies has increased by over seven-fold since 2000. The increase in the value of this market can be explained by new and improved chemotherapeutic agents now on the market, the introduction of key biologic therapies, and improved chemotherapeutic regimens which take into account various new options. The late-stage pipeline for colorectal cancer therapies is curr…
Dronedarone, a new Class III multi-channel blocking anti-arrhythmic drug currently in Phase III development by Sanofi-Aventis for the prevention of atrial fibrillation (AF) and atrial flutter (AFL) may help fill the unmet need for a safe pharmacologic treatment that effectively controls atrial fibrillation, cardiologists said this month. Sanofi-Aventis presented new data on dronedarone at the American Heart Association’s (AHA) annual scientific sessions held in Dallas.
Dronedarone, a new Class III multi-channel blocking anti-arrhythmic drug currently in Phase III development by Sanofi-Aventis for the prevention of atrial fibrillation (AF) and atrial flutter (AFL) may help fill the unmet need for a safe pharmacologic treatment that effectively controls atrial fibrillation, cardiologists sa…
Dronedarone, a new Class III multi-channel blocking anti-arrhythmic drug currently in Phase III development by Sanofi-Aventis for the prevention of atrial fibrillation (AF) and atrial flutter (AFL) may help fill the unmet need for a safe pharmacologic treatment that effectively controls atrial fibrillation, cardiologists sa…
Patients who could benefit from injectable therapies are a lot less needle-phobic than doctors assume, according to research conducted by pharmacist and behavioural scientist Professor Robert Horne. The “Open Mind” study presented at the 10th European AIDS Conference/EACS in Dublin showed over three quarters of patients would be willing to accept self-administered subcutaneous injectable therapy if offered.
Patients who could benefit from injectable therapies are a lot less needle-phobic than doctors assume, according to research conducted by pharmacist and behavioural scientist Professor Robert Horne. The “Open Mind” study presented at the 10th European AIDS Conference/EACS in Dublin showed over three quarters of patients would be willing to accept self-administered subcutane…
Patients who could benefit from injectable therapies are a lot less needle-phobic than doctors assume, according to research conducted by pharmacist and behavioural scientist Professor Robert Horne. The “Open Mind” study presented at the 10th European AIDS Conference/EACS in Dublin showed over three quarters of patients would be willing to accept self-administered subcutane…
27-Aug-2010
Caution: Your CV is your personal data. My advice as a recruiter, with many years experience in the clinical research industry, would be to take care where you send your CV and make sure your data is treated with the respect it deserves! The important thing is to be selective.
Recruitment websites can be confusing, strange places to the inexperienced. If you are not sure, select an established agency with a name you recognise. Follow the link to their website and find a contact name. Email or phone them to ask for advice. If the website doesn’t give you information about their recruiters, maybe it is best to give them a miss. Using the internet is supposed to be speedy and convenient. However, a common complaint we hear is that sending off a CV to some recruitm…
Recruitment websites can be confusing, strange places to the inexperienced. If you are not sure, select an established agency with a name you recognise. Follow the link to their website and find a contact name. Email or phone them to ask for advice. If the website doesn’t give you information about their recruiters, maybe it is best to give them a miss. Using the internet is supposed to be speedy and convenient. However, a common complaint we hear is that sending off a CV to some recruitm…
11-Mar-2021
Due to demand, we at PharmiWeb have added a new Executive Jobs Listing to our comprehensive careers section. All these jobs include packages of over £100K (GBP) per year.
We are pleased to announce that, due to demand, we have added a new section to the site. Executives in the Pharmaceutical industry can now find the best selection of jobs with packages of £100K+ (GBP) per year. These executive pharma jobs are automatically taken from our extensive database of over 4800 live jobs, provided by our partners in Agencies and PharmaCos across the industry. This means that the listing will be constantly updated with new jobs as soon as they are posted. Visit our new Executive Jobs page here.
We are pleased to announce that, due to demand, we have added a new section to the site. Executives in the Pharmaceutical industry can now find the best selection of jobs with packages of £100K+ (GBP) per year. These executive pharma jobs are automatically taken from our extensive database of over 4800 live jobs, provided by our partners in Agencies and PharmaCos across the industry. This means that the listing will be constantly updated with new jobs as soon as they are posted. Visit our new Executive Jobs page here.
